美国多发性骨髓瘤发病率和生存率按年龄、种族和民族划分的近期趋势
该研究利用监测、流行病学和最终结果(SEER)登记数据,分析1993至2012年间诊断的多发性骨髓瘤(MM)患者的发病率和相对生存率(RSR),按年龄、种族和民族分层。结果显示,5年RSR在所有年龄和种族/民族组均有改善,但10年RSR在≥75岁患者及非西班牙裔黑人中未见显著改善,提示生存改善未完全覆盖老年和少数族裔患者。
要点
- 5年相对生存率在所有年龄和种族/民族组中均有改善(1993-1997 vs 2008-2012)。
- 10年相对生存率在<65岁患者中从19.6%提高至35%(P < .001),但≥75岁患者无显著改善(7.8%-9.3%;P = .3)。
- 65-74岁患者中,10年相对生存率在非西班牙裔白人和西班牙裔中显著改善,非西班牙裔黑人未达统计学显著(P = .06)。
核心结论
- 多发性骨髓瘤患者的生存率持续改善,但进一步将改善扩展至老年和少数族裔患者仍面临挑战。
研究设计与样本
- 利用监测、流行病学和最终结果(SEER)登记数据,计算1993至2012年间诊断的多发性骨髓瘤患者的发病率和相对生存率(RSR),按诊断时期(1993-1997、1998-2002、2003-2007、2008-2012)、年龄、种族和民族分层。
主要发现
- 多发性骨髓瘤发病率在非西班牙裔白人和非西班牙裔黑人男性中显著增加,但在非西班牙裔黑人女性和西班牙裔中未显著增加。
- 5年相对生存率(1993-1997 vs 2008-2012)在所有年龄和种族/民族组中均有改善。
- 10年相对生存率(1993-1997 vs 2003-2007)在<65岁患者中从19.6%提高至35%(P < .001),但在≥75岁患者中从7.8%至9.3%无显著改善(P = .3)。
- 65-74岁患者中,10年相对生存率在非西班牙裔白人(11.3% vs 20.5%;P < .001)和西班牙裔(10.6% vs 20.2%;P = .02)中显著改善,但在非西班牙裔黑人中未达统计学显著(12.6% vs 19.5%;P = .06)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prior improvements in multiple myeloma (MM) survival were not fully observed in racial and ethnic minorities and older individuals. We hypothesized that improvements in MM management in recent years have reduced these disparities. We used the Surveillance, Epidemiology, and End Results registries to calculate the incidence and relative survival rates (RSRs) of MM in the United States for patients diagnosed from 1993 to 1997 (prethalidomide), 1998 to 2002 (introduction of thalidomide), 2003 to 2007 (bortezomib and lenalidomide), and 2008 to 2012 (upfront bortezomib and lenalidomide, early availability of carfilzomib and pomalidomide). MM incidence increased significantly among non-Hispanic whites (NHWs) and non-Hispanic black (NHB) men, but not among NHB women and Hispanics. Improvement in 5-year RSRs (1993-1997 vs 2008-2012) was seen among patients of all age and race/ethnicity groups. Ten-year RSRs (1993-1997 vs 2003-2007) improved for patients <65 years of age (19.6%-35%; P < .001), but not for patients ≥75 years of age (7.8%-9.3%; P = .3). Among patients 65 to 74 years of age, 10-year RSRs improved for NHWs (11.3% vs 20.5%; P < .001) and Hispanics (10.6% vs 20.2%; P = .02), but not for NHBs (12.6% vs 19.5%; P = .06.). These findings confirm consistent improvement in survival for MM patients and point to the challenge of further extending these improvements to older and minority patients.
引用
- Costa LJ, Brill IK, Omel J, et al. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 2017. PMID: 29296944. doi:10.1182/bloodadvances.2016002493
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。